Fig. 7
B4GALT1 inhibition augments the efficacy of anti-PD-1 therapy in LUAD. A C57BL/6 mice were implanted with 2*106 si-B4galt1 or control LLC cells that received PD-1 mAb or IgG isotype control (IgG2a) treatment. The treatment plan is shown. B Images of subcutaneous xenograft tumours harvested after euthanizing C57BL/6 mice. C, D Summary of volume and weight data of tumours. E, F Plots of tumour volumes and mouse body weights measured every 3 days. G Representative immunohistochemical images (left panel) and comparison of H-scores of PD-L1 in tumours (right panel). Scale bars, 50 μm. H Fluorescence-activated cell sorting of CD3 + in CD45 + cells, CD8 + in CD3 + T cells, and granzyme B in CD8 + T cells from xenografts and quantification. I Schematic model illustrating the mechanism of B4GALT1-mediated tumorigenesis and immune escape in LUAD. The red plus signs represent activation. *P < 0.05, **P < 0.01, n.s., not significant